New combo shrinks breast tumors before surgery in early trial
NCT ID NCT06009627
First seen Feb 16, 2026 · Last updated May 09, 2026 · Updated 11 times
Summary
This study tested a new drug (darsilide) combined with two hormone therapies (exemestane and goserelin) in 119 premenopausal women with a common type of breast cancer (HR+/HER2-). The goal was to see if this combination could shrink tumors before surgery, after initial chemotherapy had only stopped tumor growth. The main measure was the proportion of patients whose tumors shrank significantly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jie Ge
Tianjin, Tianjin Municipality, 300000, China
Conditions
Explore the condition pages connected to this study.